As reported on FiercePharma, Cingulate Therapeutics has encountered a regulatory setback in its effort to bring its lead attention-deficit/hyperactivity disorder (ADHD) therapy to market, after the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) related to manufacturing deficiencies. Importantly, the agency did not raise concerns regarding the drug’s safety or clinical effectiveness.
The CRL follows the company’s new drug application submission in July 2025 for CTx-1301, a modified-release formulation of dexmethylphenidate hydrochloride, a stimulant long used in ADHD treatment. The active ingredient has been marketed for more than two decades, most notably under the brand Focalin.
Manufacturing Issues at the Forefront
According to Cingulate, the FDA’s feedback focused exclusively on outstanding Chemistry, Manufacturing and Controls (CMC) requirements. These requests typically relate to product consistency, quality assurance, and production processes rather than clinical performance. The absence of safety or efficacy concerns suggests that the drug’s pharmacological profile remains acceptable to regulators.
Company leadership indicated that efforts to resolve these manufacturing issues are already underway. CEO Shane J. Schaffer stated that addressing the FDA’s requests is now the organization’s top priority, with the goal of resubmitting the application in a timely manner.
Drug Profile and Differentiation Strategy
CTx-1301 is designed as a once-daily, multi-core tablet that delivers dexmethylphenidate in three distinct release phases throughout the day. This delivery system aims to provide rapid onset of action paired with sustained symptom control, potentially eliminating the need for supplemental dosing later in the day—an advantage over some existing stimulant therapies.
The candidate is part of Cingulate’s broader pipeline focused on optimized drug delivery. Other programs include CTx-1302, a dextroamphetamine-based ADHD therapy, and CTx-2103, which is being evaluated as a treatment for anxiety disorders.
Financial Position Supports Next Steps
Despite the regulatory delay, Cingulate reported having more than $30 million in cash reserves, which it believes will be sufficient to complete the required manufacturing work and support a future resubmission. The company also continues to prepare for eventual commercialization, signaling confidence in the underlying asset.
Broader Industry Context
Manufacturing-related regulatory setbacks have become increasingly common across the pharmaceutical sector. Companies ranging from large biopharma firms to smaller developers have faced similar challenges when scaling production or validating processes to meet FDA standards. These issues highlight the growing importance of robust manufacturing strategies in drug development, particularly for products relying on complex delivery technologies.
Outlook
While the CRL delays CTx-1301’s path to approval, the lack of clinical concerns provides a clearer path forward. If Cingulate can quickly resolve the CMC deficiencies, the company may still be positioned to bring its differentiated ADHD therapy to market. The coming months will be critical as the company works to satisfy FDA requirements and resubmit its application.
